Clinical trials are notoriously slow, expensive, and fragile. Protocol amendments can derail timelines by months. Sites struggle to recruit the right patients. And vast pools of real-world clinical data remain underused because only specialists can query them.
TriNetX believes that equation is finally changing.
The company announced new results showing that its TriNetX LIVE™ platform—which combines clinically rich real-world data (RWD) with artificial intelligence—is materially improving how pharmaceutical companies design and execute clinical trials. The results aren’t theoretical: fewer protocol amendments, faster site identification, and more efficient recruitment are already shaping how sponsors plan studies.
Those outcomes are now driving the platform’s next evolution. In early 2026, TriNetX plans to launch natural-language AI capabilities that allow researchers to query its global network conversationally, removing long-standing technical barriers to advanced RWD analytics. The tools are currently in beta with select customers.
Taken together, the announcements point to a broader shift in clinical research: AI is moving from analytical support to structural infrastructure.
A Platform Built on Scale—and Momentum
TriNetX’s progress comes after a landmark year of growth and validation.
In 2025, the company expanded its global federated network to more than 280 million patients, spanning 220+ healthcare organizations across four continents. Its platform now maps 10,000+ clinical trial sites, a 57.5% year-over-year increase, and has supported 1,400+ peer-reviewed publications in 2025 alone, doubling the prior year’s output.
That momentum also earned TriNetX triple industry recognition, including placement on The Healthcare Technology Report’s lists of the Top 50 Healthcare Technology Companies and Top 25 Healthcare Software Companies, plus a Best of Show finalist spot at SCOPE Europe.
But scale is only part of the story. The real test is whether that data translates into better trials.
Why Clinical Development Is Ripe for AI
The economics of drug development are increasingly unforgiving. According to a 2024 JAMA Network Open analysis, the average cost to bring a new drug to market now approaches $708 million. Meanwhile, a Tufts CSDD study found that protocol amendments delay trials by an average of 260 days.
These inefficiencies are not primarily scientific—they’re operational. Sponsors struggle to define feasible eligibility criteria, select productive sites, and recruit patients efficiently.
AI-powered real-world data is emerging as a way out of that trap.
TriNetX’s approach focuses on using RWD not just for retrospective analysis, but as a planning and execution tool—one that informs decisions before trials begin and adapts as they run.
Cutting Protocol Amendments in Half
One of the most expensive failure points in clinical trials is the protocol amendment—changes made after a study has already launched because assumptions didn’t match reality.
By applying AI to real-world patient data, TriNetX helped sponsors reduce protocol amendments by up to 50% in 2025. That improvement stems from more accurate feasibility analysis upfront: eligibility criteria, endpoint definitions, and site capabilities are tested against real clinical populations before trials are locked in.
Fewer amendments mean fewer delays, lower costs, and faster paths to patients.
Rethinking Site Identification From the Patient Backward
Traditionally, sponsors identify sites first, then hope those sites can find enough eligible patients. TriNetX flips that logic.
Using its global RWD network, the platform identifies where target patients are already receiving care—then maps those locations to clinical sites. The result is a more grounded, data-driven approach to site selection.
In one collaboration with a major pharmaceutical company, this method delivered a 63% site acceptance rate, with an average response time of just nine days. For an industry accustomed to weeks or months of back-and-forth, that’s a meaningful acceleration.
Smarter Recruitment With Predictive Models
Recruitment remains the leading cause of trial delays, and TriNetX is applying machine learning to make it more predictable.
In inflammatory bowel disease, for example, the company used AI models to predict enrollment conversion rates for Crohn’s disease trials. The result: a projected jump from 33% to 85% conversion by targeting patients more precisely and engaging them more effectively.
Rather than casting wider nets, sponsors can focus effort where it’s most likely to succeed.
AI for Earlier Disease Detection
TriNetX’s AI applications extend beyond trial logistics into earlier disease identification.
In collaboration with leading research institutions, the company developed an AI model for pancreatic cancer that predicts who is at risk of developing the disease within the next 18 months. The model identifies 87 predictive features and supports customizable risk thresholds depending on clinical goals.
That flexibility allows the model to be used in multiple ways: flagging high-risk patients for immediate imaging, acting as a standalone early detection tool, or supporting broader screening followed by biomarker testing. The model is now being validated on a prospective cohort of six million patients.
If successful, it could materially shift outcomes in one of the deadliest and hardest-to-detect cancers.
2026: Making Advanced Analytics Conversational
The most consequential change may arrive in 2026, when TriNetX rolls out conversational AI within TriNetX LIVE™.
Instead of constructing complex queries, researchers will be able to ask questions in natural language—such as identifying eligible patient populations, estimating feasibility, or comparing site performance—and receive traceable, real-time analyses.
The system is powered by TriNetX’s proprietary clinical ontology and taxonomy, ensuring that insights remain consistent, explainable, and continuously refreshed from its live provider network.
This shift lowers the barrier to entry for advanced RWD analytics, expanding access beyond data scientists to clinicians, trial managers, and medical strategists.
APIs and the Path Toward Agentic AI
TriNetX is also expanding its API capabilities, allowing partners to submit queries—via code or natural language—directly from their existing systems. Those integrations return live patient counts, feasibility insights, and site intelligence embedded into current workflows.
By reducing data silos and enabling system-to-system intelligence, TriNetX is laying groundwork for agentic AI—where autonomous systems can monitor feasibility, adapt recruitment strategies, and surface recommendations without constant human prompting.
That vision aligns with broader trends across life sciences, where AI is moving from decision support to semi-autonomous orchestration.
The Bigger Implication: Speed as a Clinical Advantage
For patients, the impact of these improvements is not abstract. Faster trials mean earlier diagnoses, quicker access to therapies, and fewer months—or years—waiting for treatment options.
TriNetX COO Steve Kundrot framed the company’s growth metrics as something more human than scale. Each data point, he noted, represents a real outcome: trials filling faster, diseases detected earlier, therapies reaching patients sooner.
As AI continues to reshape healthcare, TriNetX’s trajectory suggests that the biggest gains may come not from new algorithms alone, but from making intelligence accessible, operational, and deeply embedded in how clinical research actually runs.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
